The North America Non-invasive Prenatal Testing (NIPT) Market would witness market growth of 17.4% CAGR during the forecast period (2023-2030).
One notable trend in the market is the continuous expansion of the test menu. Initially focused on common chromosomal abnormalities, NIPT is now increasingly capable of detecting a wider range of conditions, including microdeletions and rare genetic disorders. Advances in genetic sequencing and bioinformatics drive this expansion of capabilities. The market has seen substantial growth in market size and revenue. The increasing demand for NIPT services and the development of new applications have fuelled the market's expansion.
NIPT is increasingly becoming accessible in emerging markets owing to partnerships between diagnostic companies and local healthcare providers. This trend is improving the availability of NIPT to a broader demographic. Integrating artificial intelligence (AI) and machine learning in NIPT data analysis is becoming more prevalent. These technologies enhance the accuracy of results and enable more precise detection of abnormalities. Some NIPT providers offer consumer-initiated testing, allowing pregnant individuals to request and pay for NIPT without needing a healthcare provider's prescription. This trend empowers individuals to take control of their prenatal care.
In North America, access to prenatal care can vary based on geographic location, socioeconomic status, and insurance coverage. Efforts are made to improve access, particularly for vulnerable populations. According to the data released by the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), 35 HRSA-funded health institutions received more than $65 million from the Government to address maternal mortality cases. Therefore, rising prenatal care investment in North America will boost the region's demand for non-invasive prenatal testing.
The US market dominated the North America Non-invasive Prenatal Testing (NIPT) Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,133.9 Million by 2030. The Canada market is experiencing a CAGR of 20.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 19% during (2023 - 2030).
Based on Product, the market is segmented into Consumables & Reagents, and Instruments. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome, and Others. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics. Based on Technology, the market is segmented into Next Generation Sequencing (NGS), Microarray, Polymerase Chain Reaction (PCR), and Rolling Circular Amplification. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Non-invasive Prenatal Testing (NIPT) Market is Predict to reach USD 17.7 Billion by 2030, at a CAGR of 18.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Illumina, Inc., Natera Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific SE, Thermo Fisher Scientific, Inc., GE HealthCare Technologies, Inc., Agilent Technologies, Inc., and Pacific Biosciences of California, Inc.
By Product
By Application
By End User
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
